Epidermal growth factor receptor (EGFR)1 targeting therapy has been the prototype example of successful precision medicine ever since it revolutionized the treatment of non-small cell lung cancer (NSCLC) 15 years ago. This evidence concerns the gene EGFR and non-small cell lung carcinoma.